Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer

  • Aguado, Cristina
  • Teixidó, Cristina|||0000-0002-7226-6567
  • Román, Ruth
  • Reyes, Roxana
  • Giménez-Capitán, Ana|||0000-0003-2575-1225
  • Marin, Elba|||0000-0001-8882-7552
  • Cabrera-Lopez, Carlos|||0000-0002-6251-4854
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Castillo, Sergi
  • Muñoz, Silvia
  • Arcocha, Ainara
  • López Vilaró, Laura|||0000-0002-5428-8017
  • Sullivan, Ivana|||0000-0002-0434-3436
  • Aldeguer, Erika
  • Rodríguez, Sonia
  • Moya, Irene
  • Viteri, Santiago|||0000-0002-7572-1123
  • Cardona Zorrilla, Andrés Felipe|||0000-0003-3525-4126
  • Palmero, Ramon
  • Sainz, Cristina
  • Mesa-Guzmán, Miguel
  • Lozano, Maria D.
  • Aguilar-Hernández, Andrés
  • Martínez-Bueno, Alejandro
  • González-Cao, María|||0000-0003-3791-540X
  • Gonzalvo, Elena
  • Leenders, William P. J.
  • Rosell, Rafael|||0000-0003-0817-3400
  • Montuenga, Luis M.
  • Prat, Aleix|||0000-0003-2377-540X
  • Molina Vila, Miguel Ángel|||0000-0001-8866-9881
  • Reguart, Noemi|||0000-0001-8190-499X
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3.5% with very-high MET mRNA expression, a surrogate of MET amplification. MET alterations identified by nCounter correlated with clinical benefit from MET inhibitors. Quantitative mRNA-based techniques can improve the selection of patients for MET-targeted therapies. MET inhibitors have shown activity in non-small-cell lung cancer patients (NSCLC) with MET amplification and exon 14 skipping (METΔex14). However, patient stratification is imperfect, and thus, response rates have varied widely. Here, we studied MET alterations in 474 advanced NSCLC patients by nCounter, an RNA-based technique, together with next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and reverse transcriptase polymerase chain reaction (RT-PCR), exploring correlation with clinical benefit. Of the 474 samples analyzed, 422 (89%) yielded valid results by nCounter, which identified 13 patients (3%) with MET Δex14 and 15 patients (3.5%) with very-high MET mRNA expression. These two subgroups were mutually exclusive, displayed distinct phenotypes and did not generally coexist with other drivers. For MET Δex14, 3/8 (37.5%) samples positive by nCounter tested negative by NGS. Regarding patients with very-high MET mRNA, 92% had MET amplification by FISH and/or NGS. However, FISH failed to identify three patients (30%) with very-high MET RNA expression, among which one received MET tyrosine kinase inhibitor treatment deriving clinical benefit. Our results indicate that quantitative mRNA-based techniques can improve the selection of patients for MET-targeted therapies.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

  • Valencia, Karmele
  • Echepare, Mirari
  • Teijeira, Álvaro
  • Pasquier, Andrea
  • Bértolo, Cristina
  • Sáinz, Cristina
  • Tamayo Uria, Ibon
  • Picabea, Beñat
  • Bosco, Graziella
  • Thomas, Roman
  • Agorreta Arrazubi, Jackeline
  • López-Picazo, José María
  • Frigola, Joan
  • Amat, Ramón
  • Calvo, Alfonso
  • Felip, Enriqueta
  • Melero, Ignacio
  • Montuenga, Luis M.
Lung cancer remains the leading cause of cancer-related death worldwide. We identify DSTYK, a dual serine/threonine and tyrosine non-receptor protein kinase, as a novel actionable target altered in non-small cell lung cancer (NSCLC). We also show DSTYK's association with a lower overall survival (OS) and poorer progression-free survival (PFS) in multiple patient cohorts. Abrogation of DSTYK in lung cancer experimental systems prevents mTOR-dependent cytoprotective autophagy, impairs lysosomal biogenesis and maturation, and induces accumulation of autophagosomes. Moreover, DSTYK inhibition severely affects mitochondrial fitness. We demonstrate in vivo that inhibition of DSTYK sensitizes lung cancer cells to TNF-α–mediated CD8+-killing and immune-resistant lung tumors to anti–PD-1 treatment. Finally, in a series of lung cancer patients, DSTYK copy number gain predicts lack of response to the immunotherapy. In summary, we have uncovered DSTYK as new therapeutic target in lung cancer. Prioritization of this novel target for drug development and clinical testing may expand the percentage of NSCLC patients benefiting from immune-based treatments., This work was supported by Fundación para la investigación medica aplicada (FIMA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC; CB16/12/00443), Spanish Association Against Cancer Scientific Foundation (AECC; GCB14-2170), Fundación Ramón Areces, Instituto de Salud Carlos III, and cofunded by the European Union (European Regional Development Fund, “A way to make Europe”; PI19/00098; PI19/00230; PI20/ 00419), Fundación Roberto Arnal Planelles, and International Association for the Study of Lung Cancer (IASLC) Fellowship funding (K. Valencia). M. Echepare was supported by Contratos Predoctorales de Formación en Investigación en Salud (PFIS), Instituto de Salud Carlos III, and co-funded by the European Union (European Social Fund, "Investing in your future"; FI20/00295).